Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
62
-
Total 13F shares, excl. options
-
24.1M
-
Shares change
-
+164K
-
Total reported value, excl. options
-
$92.4M
-
Value change
-
-$11.1M
-
Put/Call ratio
-
0.81
-
Number of buys
-
27
-
Number of sells
-
-46
-
Price
-
$3.83
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q4 2018
97 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q4 2018.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 62 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.1M shares
of 193M outstanding shares and own 12.48% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (4.34M shares), PRIMECAP MANAGEMENT CO/CA/ (4.04M shares), EcoR1 Capital, LLC (3.28M shares), BlackRock Inc. (2.42M shares), LADENBURG THALMANN FINANCIAL SERVICES INC. (1.77M shares), Foresite Capital Management IV, LLC (1.58M shares), MORGAN STANLEY (1.09M shares), BANK OF MONTREAL /CAN/ (968K shares), Hudson Bay Capital Management LP (650K shares), and STATE STREET CORP (598K shares).
This table shows the top 62 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.